venous glucose
Recently Published Documents


TOTAL DOCUMENTS

35
(FIVE YEARS 3)

H-INDEX

11
(FIVE YEARS 0)

2021 ◽  
Vol 9 (2) ◽  
pp. e002556
Author(s):  
Andrew Yen Siong Tan ◽  
Mui Suan Tan ◽  
Ashley Wu ◽  
Ai Choo Seah ◽  
Cecilia Chong ◽  
...  

IntroductionEarly diagnosis of prediabetes based on blood sampling for the oral glucose tolerance test (OGTT) is crucial for intervention but multiple barriers hinder its uptake. This study aimed to assess the feasibility and precision of a self-administered capillary OGTT for type-2 diabetes mellitus (T2DM) in high-risk individuals.Research design and methodsParticipants with history of gestational diabetes or prediabetes were recruited in primary care. Due to their prediabetic status and previous diagnosis of gestational diabetes mellitus, a proportion of participants had previous experience doing OGTT. They self-administered the capillary OGTT and concurrently their venous glucose samples were obtained. They filled a questionnaire to collect their demographic information, views of their capillary OGTT, and their preferred site of the test.ResultsAmong 30 participants enrolled in this feasibility study, 93.3% of them felt confident of performing the capillary OGTT themselves, and 70.0% preferred the test at home. Older, less educated participants found it less acceptable. Mean capillary glucose values were significantly higher than venous glucose values, with mean difference at 0.31 mmol/L (95% CI 0.13 to 0.49) at fasting, and 0.47 mmol/L (95% CI 0.12 to 0.92) 2 hours post-OGTT. Capillary and venous glucose measurements were correlated for fasting (r=0.95; p<0.001) and 2-hour-post-OGTT (r=0.95;p<0.001). The Fleiss-Kappa Score (0.79, p<0.0001) indicated fair agreement between the two methods. The capillary OGTT had excellent sensitivity (94.1%) and negative predictive value (NPV=91.7%) in identifying prediabetes or T2DM status, vis-a-vis to venous glucose samples.ConclusionSelf-administered capillary OGTT is feasible and acceptable, especially among younger adults, with excellent sensitivity and NPV compared with plasma-based OGTT.


BJS Open ◽  
2021 ◽  
Vol 5 (2) ◽  
Author(s):  
M O Hamed ◽  
A D Barlow ◽  
N Dolezalova ◽  
S Khosla ◽  
A Sagar ◽  
...  

Abstract Background There is an unmet need for suitable ex vivo large animal models in experimental gastroenterology and intestinal transplantation. This study details a reliable and effective technique for ex vivo normothermic perfusion (EVNP) of segmental porcine small intestine. Methods Segments of small intestine, 1.5–3.0 m in length, were retrieved from terminally anaesthetized pigs. After a period of cold ischaemia, EVNP was performed for 2 h at 37°C with a mean pressure of 80 mmHg using oxygenated autologous blood diluted with Ringer’s solution. The duration of EVNP was extended to 4 h for a second set of experiments in which two segments of proximal to mid-ileum (1.5–3.0 m) were retrieved from each animal and reperfused with whole blood (control) or leucocyte-depleted blood to examine the impact of leucocyte depletion on reperfusion injury. Results After a mean cold ischaemia time of 5 h and 20 min, EVNP was performed in an initial group of four pigs. In the second set of experiments, five pigs were used in each group. In all experiments bowel segments were well perfused and exhibited peristalsis during EVNP. Venous glucose levels significantly increased following luminal glucose stimulation (mean(s.e.m.) basal level 1.8(0.6) mmol/l versus peak 15.5(5.8) mmol/l; P &lt; 0.001) and glucagon-like peptide 1 (GLP-1) levels increased in all experiments, demonstrating intact absorptive and secretory intestinal functions. There were no significant differences between control and leucocyte-depleted animals regarding blood flow, venous glucose, GLP-1 levels or histopathology at the end of 4 h of EVNP. Conclusions This novel model is suitable for the investigation of gastrointestinal physiology, pathology and ischaemia reperfusion injury, along with evaluation of potential therapeutic interventions.


2021 ◽  
Vol 43 (1) ◽  
pp. 63-68
Author(s):  
Juan David Farfán-Albarracín ◽  
Cristina Lorena Ramírez-Sierra ◽  
Oscar Mauricio Espitia Segura ◽  
Sofy Helena Pérez ◽  
Hugo Andrés Téllez Prada ◽  
...  

PLoS ONE ◽  
2020 ◽  
Vol 15 (8) ◽  
pp. e0237215
Author(s):  
Simona Panunzi ◽  
Marcello Pompa ◽  
Alessandro Borri ◽  
Vincenzo Piemonte ◽  
Andrea De Gaetano

2018 ◽  
Vol 1 (01) ◽  
pp. 1-4
Author(s):  
Bibek Rajbhandari ◽  
Tirtha Man Shrestha ◽  
Ramesh Aacharya

Introduction: This study was done to determine the mean difference and correlation between fasting capillary and venous glucose estimation. Methods: This was cross-sectional analytic study done in United Mission Hospital, Palpa, Tansen. Calculated sample size was 92, convenience sampling technique was used. During 5 month of duration in 92 diabetic patients, where fasting capillary and venous glucose were performed consecutively. Confounding was ruled out with matching approach, adjustment tests were also used like X2 Mantel -Haenszel and logistic regression. Reporting guideline of this observational study was done with the help of SROBE guidelines. Results: The mean venous blood glucose was 9.52% higher than the Mean capillary glucose. A strong correlation was observed between venous and capillary blood glucose, with Pearson correlation coefficient of 0.94. Conclusions: There is a significant difference in the blood glucose results analyzed on a bedside glucometer when the samples are taken from capillary or venous sources. Although good correlation is between venous and capillary derived samples, caution must be exercised in accepting the results as equivalent or using either as substitutes for a laboratory blood glucose result.


2018 ◽  
Vol 124 (4) ◽  
pp. 1054-1061 ◽  
Author(s):  
Timothy D. Heden ◽  
Ying Liu ◽  
Jill A. Kanaley

Resistance exercise during the postprandial period lowers venous glucose concentrations in individuals with type 2 diabetes, but the impact of resistance exercise on interstitial glucose concentrations is not well understood. The objective of this study was to compare subcutaneous adipose tissue interstitial glucose and venous blood glucose concentrations during postprandial resistance exercise in patients with type 2 diabetes. Eleven individuals completed two trials in a random order including a no-exercise (NoEx) and a postprandial resistance exercise trial (M-Ex). During the trials, the individuals consumed a meal and either remained sedentary (NoEx) or performed a session of resistance training beginning 45 min after the meal (M-Ex) while interstitial and venous glucose concentrations were simultaneously measured. Venous glucose during exercise was ~11% lower ( P = 0.05) during M-Ex (8.0 ± 0.5 mmol/l) compared with NoEx (9.0 ± 0.5 mmol/l) whereas interstitial glucose during M-Ex (10.4 ± 0.7 mmol/l) was not different compared with interstitial glucose during NoEx (10.1 ± 0.7 mmol/l). Bland-Altman plots revealed that the difference (bias) between interstitial and venous glucose during exercise was more than twofold greater during M-Ex (2.36 ± 2.07 mmol/l) compared with NoEx (1.11 ± 1.69 mmol/l). The mean (33.8 ± 6.2 mmol/l) and median (34.7 ± 6.3 mmol/l) absolute relative difference during exercise were 73% and 78% greater compared with the mean (19.5 ± 4.1 mmol/l) and median (19.5 ± 4.1 mmol/l) absolute relative difference during NoEx ( P = 0.04). Resistance exercise has unequal effects on glucose concentrations within different bodily compartments as exercise reduced venous glucose concentrations but not adipose tissue interstitial glucose concentrations in the abdominal region in individuals with type 2 diabetes. NEW & NOTEWORTHY This is the first study to compare subcutaneous adipose tissue interstitial glucose concentrations and venous blood glucose concentrations during postprandial resistance exercise in individuals with type 2 diabetes. We find that resistance exercise effectively reduces systemic venous blood glucose concentrations but not subcutaneous adipose tissue interstitial glucose concentrations in the abdominal region. Resistance exercise has differential effects on glucose concentrations depending on its compartmentalization within the body.


Author(s):  
Ploutarchos Tzoulis ◽  
Richard W Corbett ◽  
Swarupini Ponnampalam ◽  
Elly Baker ◽  
Daniel Heaton ◽  
...  

Summary Five days following the 3rd cycle of nivolumab, a monoclonal antibody, which acts as immune checkpoint inhibitor against the programmed cell death protein-1, for metastatic lung adenocarcinoma, a 56-year-old woman presented at the hospital critically ill. On admission, she had severe diabetic ketoacidosis (DKA), as evidenced by venous glucose of 47 mmol/L, blood ketones of 7.5 mmol/L, pH of 6.95 and bicarbonate of 6.6 mmol/L. She has had no personal or family history of diabetes mellitus (DM), while random venous glucose, measured 1 week prior to hospitalisation, was 6.1 mmol/L. On admission, her HbA1c was 8.2% and anti-GAD antibodies were 12 kIU/L (0–5 kU/L), while islet cell antibodies and serum C-peptide were undetectable. Nivolumab was recommenced without the development of other immune-mediated phenomena until 6 months later, when she developed hypothyroidism with TSH 18 U/L and low free T4. She remains insulin dependent and has required levothyroxine replacement, while she has maintained good radiological and clinical response to immunotherapy. This case is notable for the rapidity of onset and profound nature of DKA at presentation, which occurred two months following commencement of immunotherapy. Despite the association of nivolumab with immune-mediated endocrinopathies, only a very small number of patients developing type 1 DM has been reported to date. Patients should be closely monitored for hyperglycaemia and thyroid dysfunction prior to and periodically during immunotherapy. Learning points: Nivolumab can induce fulminant type 1 diabetes, resulting in DKA. Nivolumab is frequently associated with thyroid dysfunction, mostly hypothyroidism. Nivolumab-treated patients should be monitored regularly for hyperglycaemia and thyroid dysfunction. Clinicians should be aware and warn patients of potential signs and symptoms of severe hyperglycaemia.


2016 ◽  
Vol 10 (4) ◽  
pp. 876-884 ◽  
Author(s):  
Mervi Andelin ◽  
Jort Kropff ◽  
Viktorija Matuleviciene ◽  
Jeffrey I. Joseph ◽  
Stig Attvall ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document